Profil
David Konciak worked as the Head of Worldwide Immuno Oncology at Bristol Myers Squibb Co. He then worked as the VP of Business Development & Strategic Portfolio at Surface Oncology, Inc. from 2018 to 2020.
Konciak received his undergraduate degree from Muhlenberg College and his MBA from The Wharton School of the University of Pennsylvania.
Ehemalige bekannte Positionen von David Konciak
| Unternehmen | Position | Ende |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 01.01.2020 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Ausbildung von David Konciak
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Muhlenberg College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
